Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.

Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range o...

After surging to unprecedented peaks in 2021, Pfizer Inc. (NYSE: PFE) faced extreme challenges in 2023, marking a significant downturn for the world's largest drugmaker.

U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further...

Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.

Pfizer (PFE) shares tumbled over 8% in early trading Wednesday to their lowest level in more than 10 years after warning revenue could decline next year and releasing guidance below forecasts as de...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two importa...

Pfizer Inc (NYSE:PFE) said today that it is expecting $58.5 billion to $61.5 billion of sales in 2024 from Covid-19 vaccines, antiviral medicine Paxlovid and Seagen, with deal for the latter cancer...

After raking in billions from Covid products, Pfizer has struggled to navigate a world beyond the pandemic and reassure investors about its growth potential.

Pfizer stock's struggles continued Wednesday, as shares of the healthcare titan dropped to their lowest level since before the Covid-19 pandemic, the latest dubious milestone for the battered stock...

Pfizer Inc (NYSE: PFE) opened about 9.0% down on Wednesday after its management issued guidance for the coming year that fell short of Street estimates. Pfizer's earnings and revenue outlook for 20...

Pfizer shares have fallen 6.8% in pre-market trading after it forecast revenue and earnings below analyst expectations.  The pharmaceutical giant said sales will reach $58.5 billion to $61.5 billio...

The pharmaceutical company said it expects adjusted earnings per share in the range of $2.05 to $2.25 for 2024. Wall Street was looking for $3.16.

Pfizer Inc.'s stock PFE, -0.21% slid 7% premarket Wednesday, after the drug company set guidance for 2024 that lagged consensus. Pfizer, which is hosting an investor day later Wednesday, is expecti...

Bullish options traders are having a field day with Pfizer Inc. (NYSE:PFE), after the pharma company received all the regulatory approvals necessary to finalize its $43 billion acquisition of Seage...